Bone fractures and segmental bone defects are a significant source of patient morbidity and
place a staggering economic burden on the healthcare system. The annual cost of treating …

Osteonecrosis of the femoral head is a disabling pathology affecting a young population
(average age at treatment, 33 to 38 years) and is the most important cause of total hip …

It is estimated that 20000 to 30000 new patients are diagnosed with osteonecrosis annually
accounting for approximately 10% of the 250000 total hip arthroplasties done annually in the …

Epigallocatechin‐3‐gallate (EGCG), a component extracted from green tea, has been
proved to have multiple effects on human pathological and physiological processes, and its …

The worldwide incidence of bone disorders and conditions has trended steeply upward and
is expected to double by 2020, especially in populations where aging is coupled with …

Osteonecrosis of the femoral head (ONFH) is a devastating and complicated disease with an
unclear etiology. Femoral head‐preserving surgeries have been devoted to delaying and …

Stem-cell-mediated bone repair has been used in clinical trials for the regeneration of large
craniomaxillofacial defects, to slow the process of bone degeneration in patients with …

Mesenchymal stem cells (MSCs) are partially defined by their ability to differentiate into
tissues including bone, cartilage and adipose in vitro, but it is their trophic, paracrine and …

Mesenchymal stem cells (MSCs) are increasingly being used in tissue engineering and cell-
based therapies in all fields ranging from orthopedic to cardiovascular medicine. Despite …

OBJECTIVE: Various preparative protocols have been proposed for the acquisition and
cultivation of mesenchymal stem cells (MSC). Whereas surface antigen markers have failed …